Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1326 participants.

Also called NCT01999218

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; double masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,326 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01999218
  • EudraCT 2013-003582-34
Other papers using this trial's data
  • Results of VERTIS SU extension study: safety and efficacy of ertugliflozin treatment over 104 weeks compared to glimepiride in patients with type 2 diabetes mellitus inadequately controlled on metformin Current medical research and opinion, 2019-08 DOI, PubMed 30760125

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
Not reported
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01999218. Randomized; double masking; primary purpose treatment. Start 2013-12-16 (actual); primary completion 2017-04-18 (actual). Results posted on 2018-05-11.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Ertugliflozin vs. Glimepiride in Type 2 Diabetes Mellitus (T2DM) Participants on Metformin (MK-8835-002)
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Ertugliflozin 5 mg
Intervention (Drug)
Ertugliflozin 10 mg
Intervention (Drug)
Glimerpiride
Intervention (Drug)
Placebo to Ertugliflozin
Intervention (Drug)
Placebo to Glimepiride
Intervention (Drug)
Metformin
Intervention (Drug)
Sitagliptin
Lead sponsor
Merck Sharp & Dohme LLC (class: industry)
Collaborator
Pfizer (class: industry)

Record details

Record id
cardio:ct-nct01999218
Content hash
b9f954266e9fa714f2d1d0fd93f952f11e93622b4865167e32e34ffcbe0cd4ed